Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by skys1 on Oct 20, 2023 8:46am

MY TAKE

I disagree with the reasons voiced for the recent spate of very positive news releases over a short period of time as a set up etc. IMO, they were put forth not only for PR purposes of course, but also to be very helpful to Dr. Lbiati in her efforts with pharmas and biotechs around the world. They will be very useful to her in opening and or continued discussions with potential business or financial partners in this sector which she has been very successful at doing in the past. I suspect her efforts are showing success as Roger recently gave her(and only her), a large grant of options - very unusual for one person to be singled out by Roger like that. Since the grant and PRs all occured around the same time, I surmise they were related. I suspect something on the results of her efforts will be announced in the not too distant future as I posted a couple weeks ago, I believe there is something going on or in the works. If so, that will be a game changer. That's MY TAKE on this unusual group of press releases.
Comment by skyhawk1 on Oct 20, 2023 9:32am
I agree! Excellent observation! The timing of the announcements definitely seems to suggest a clear connection between the two of them! Cheers ~ SUPERLONGS!! ~ 
Comment by patience69 on Oct 20, 2023 11:23am
I can't agree with you more skys. Its defintely not too early for some sort of a royalty deal. Hopefully that would give us the cash to get as far as a phase 2 on another indication. My personal guess is should we have excellent results start to trickle in on another indication & a path to AA  for bladder then we are in buyout territory.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250